Literature DB >> 12604892

Primary and secondary cutaneous diffuse large B-cell lymphomas: a multiparameter analysis of 25 cases including fluorescence in situ hybridization for t(14;18) translocation.

Bong K Kim1, Urvashi Surti, Amit G Pandya, Steven H Swerdlow.   

Abstract

Although primary cutaneous diffuse large B-cell lymphomas (DLBCLs) except for those of the leg are grouped together with primary cutaneous follicle center cell lymphoma in the European Organization for Research and Treatment of Cancer classification of primary cutaneous lymphomas, they typically lack the usual phenotypic profile of follicular lymphoma. Whether they are truly of follicular center cell origin, have a molecular pathogenesis similar to nodal follicular lymphoma, or have any biologic features that distinguish them from secondary DLBCL involving skin remains uncertain. To address these issues, a retrospective multiparameter study of 25 patients including clinical, histologic, immunophenotypic, and cytogenetic analyses was performed. A classic CD10+, bcl-6+ follicular center cell profile was found in 10 (40%) cutaneous DLBCL (2 of 11 primary, 5 of 8 secondary, 3 of 6 unclassified) with bcl-2 expression seen only in the nonprimary cases. Of the remaining cases, 14 cases (56%) were CD10-, bcl-6+, bcl-2+/- (9 primary) and one case (4%) was CD10-, bcl-6-, bcl-2+ (0 primary). Fluorescence in situ hybridization analysis showed a t(14;18) in 0 of 9 primary and 3 of 5 secondary cases. Primary cases were frequently found in the head/neck region, whereas secondary cases were more common on the trunk and extremities. Patients with primary disease were all alive, usually having received only local therapy, at a median follow-up of 19 months. Most secondary cases were treated with chemotherapy with only one untreated patient dead of disease at a median follow-up of 5 months. Primary cutaneous DLBCLs therefore appear to be distinctive as they have fewer features of follicular lymphoma than do secondary cases. Nevertheless, some appear to be of follicular center cell origin, even though they probably have a different molecular pathogenesis than most nodal follicular lymphomas.

Entities:  

Mesh:

Year:  2003        PMID: 12604892     DOI: 10.1097/00000478-200303000-00009

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  5 in total

1.  [A progressive ulcerative neck mass on the left infraauricular area].

Authors:  M A Broglie; M Tinguely; F Stenner; S J Stöckli
Journal:  HNO       Date:  2008-10       Impact factor: 1.284

2.  Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.

Authors:  Porcia T Bradford; Susan S Devesa; William F Anderson; Jorge R Toro
Journal:  Blood       Date:  2009-03-11       Impact factor: 22.113

3.  A Literature Revision in Primary Cutaneous B-cell Lymphoma.

Authors:  R La Selva; S Alberti Violetti; C Delfino; V Grandi; S Cicchelli; C Tomasini; M T Fierro; E Berti; N Pimpinelli; P Quaglino
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

Review 4.  Radiotherapy of primary cutaneous follicle center lymphoma: case report and review of literature.

Authors:  Romana Ceovic; Ivana Jovanovic; Kresimir Kostovic; Jaka Rados; Snjezana Dotlic; Ivo Radman; Sandra Marinovic Kulisic; Davorin Loncaric
Journal:  Radiat Oncol       Date:  2013-06-20       Impact factor: 3.481

5.  Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.

Authors:  Marco Lucioni; Emilio Berti; Luca Arcaini; Giorgio A Croci; Aldo Maffi; Catherine Klersy; Gaia Goteri; Carlo Tomasini; Pietro Quaglino; Roberta Riboni; Mariarosa Arra; Elena Dallera; Vieri Grandi; Mauro Alaibac; Antonio Ramponi; Sara Rattotti; Maria Giuseppina Cabras; Silvia Franceschetti; Giulio Fraternali-Orcioni; Nicola Zerbinati; Francesco Onida; Stefano Ascani; Maria Teresa Fierro; Serena Rupoli; Marcello Gambacorta; Pier Luigi Zinzani; Nicola Pimpinelli; Marco Santucci; Marco Paulli
Journal:  Cancer Med       Date:  2016-09-26       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.